Scott W. Morrison - 12 Jun 2025 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Reporting relationship: Director
Issuer ticker: TARS
Reported as of: 12 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jun 2025, 16:04:12 UTC
Prior SEC filing: 16 May 2025
Next SEC filing: 23 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Scott Sieckert, Attorney-in-Fact

Key filing fact

Scott W. Morrison filed Form 4 for Tarsus Pharmaceuticals, Inc. (TARS) on 16 Jun 2025.

Key facts

This page summarizes Scott W. Morrison's Form 4 filing for Tarsus Pharmaceuticals, Inc. (TARS).
4 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 16 Jun 2025, 16:04.

Change

Previous filing in this sequence was filed on 16 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001662426 Primary reporting owner

Morrison Scott W

Relationship: Director
Address: 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE
Signature: /s/ Scott Sieckert, Attorney-in-Fact
Signature date: 16 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TARS transaction

Common Stock

Options Exercise

Transaction value
Shares: +3,350
Change %
Price
Shares after: 3,350
Date: 13 Jun 2025
Ownership: Direct
Footnotes: F1

TARS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 6,016
Date: 12 Jun 2025
Ownership: By Morrison-Minton Family 2004 Trust

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TARS transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +4,540
Change %
Price: $0.000000
Shares after: 4,540
Date: 12 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,540
Exercise price: $40.95
Footnotes: F2

TARS transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +2,954
Change %
Price: $0.000000
Shares after: 2,954
Date: 12 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,954
Exercise price
Footnotes: F3, F4

TARS transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -3,350
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 13 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,350
Exercise price
Footnotes: F3, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

Footnote F2

Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Footnote F3

Each RSU represents a contingent right to receive one share of the Company's common stock.

Footnote F4

RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Footnote F5

RSUs granted on June 13, 2024, in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.